dry mouth with tirzepatide Does Cause Tooth Decay? Evidence and Prevention How To Treat Dry Mouth?

We explore the ESPRs implications for M&A and outline what businesses should be doing in response

For detailed comparison, see our Mounjaro vs Ozempic guide

Many of the cardiovascular and metabolic trials informing the discussion were not designed to evaluate ophthalmic outcomes. The authors called for prospective ophthalmology-specific studies incorporating imaging biomarkers, visual outcomes and disease-specific monitoring, noting that parsing the protective benefits or adverse effects of this rapidly growing medication class will be essential to refining disease management and improve patient outcomes. As GLP-1 therapies become increasingly common among patients with diabetes, obesity and vascular comorbiditiesprecisely the populations populating ophthalmic clinicsthe field may not have the luxury of waiting for cleaner data

Why Your Genetics Matter More Than Average Data Four genetic variants emerge as key predictors of GLP-1 medication response: GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313

A GLP-1 receptor agonist inhibits aldosterone release in healthy volunteers

47 In patients with overweight or obesity without diabetes, the Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) trial showed that tirzepatide 15 mg weekly led to a mean body weight reduction of 20.9% after 72 weeks of treatment, compared with 3.1% with placebo